Feedstock Additive Co. Gets Massive Order for Brazil Market

  ()
The widespread use of antibiotics in animal feeds, as well as over-prescription by physicians for therapeutic treatment of human infections, is leading to a growing resistance to antibiotics that is killing close to 1 million people each year. One company believes it has developed at least part of the solution through a beta carotene food additive that boosts immunity and contributes to better overall health.

Demand for Co.’s Antibiotic Free Animal Feed Is Raising

Contributed Opinion
  ()
With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.'s antibiotic free animal feed seems to be just what they're looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company.

Testing Confirms Drug Candidate Differs From Peers

Research Report
  ()
Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report.

Biotech Co. Awakes To Good News

Contributed Opinion
  ()
Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development.

Biopharma Co. Planning BLA for DMD Drug

Research Report
  ()
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares.

Environmental Tech Co. Builds up to a Major Bull Market

Contributed Opinion
  ()
After a few weeks of observation, expert Clive Maund believes Bion Environmental Technologies Inc. may be due for a major uptrend and is building up to a major bull market.

MRI Device Maker's Earnings Come In at High End of Forecasts

Research Report
  ()
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins, and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40).

Tech Co. ‘Right at the Point of Breakout'

Contributed Opinion
  ()
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.

Expert Believes Health Co. Blooms With Opportunity

Contributed Opinion
  ()
Expert Clive Maund touches on the latest news with Bloom Health Partners Inc. from the enthusiastic buying toward the end of June to whether he believes the health company is still bullish.

Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study

Contributed Opinion
  ()
Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil.

Expert Investing Ideas

"It would be logical for AGN to develop ifenprodil for two indications."

–André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–André Uddin, Research Capital Corporation


"AWKNF's key programs are on track."

–Patrick Trucchio, H.C. Wainwright & Co.


"AWKNF's KARE program is on track to advance to Phase 3 in H2/22."

–Patrick Trucchio, H.C. Wainwright & Co.


"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


"AGN's current valuation is favorable from a risk-reward standpoint."

–André Uddin, Research Capital Corporation


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment

Research Report
  ()
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.

Analyst Update

Additional Study Review Reveals Patients Coughed Much Less

  ()
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.

Biotech Co. Granted New Patent for Breast Cancer Vaccine

Research Report
  ()
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa.